DarioHealth Stock (NASDAQ:DRIO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$7.21

52W Range

$5.93 - $17.74

50D Avg

$7.61

200D Avg

$10.49

Market Cap

$52.65M

Avg Vol (3M)

$12.24K

Beta

1.08

Div Yield

-

DRIO Company Profile


DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

196

IPO Date

Mar 14, 2016

Website

DRIO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Service$14.93M$20.20M-
Services--$13.08M
Consumers--$8.29M

Fiscal year ends in Dec 25 | Currency in USD

DRIO Financial Summary


Dec 25Dec 24Dec 23
Revenue$22.36M$27.04M$20.35M
Operating Income$-36.66M$-57.74M$-56.19M
Net Income$61.73M$-42.75M$-59.43M
EBITDA$-36.66M$-50.32M$-54.38M
Basic EPS$10.12$0.61$-1.93
Diluted EPS$10.12$-0.61$-1.93

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Mar 19, 26 | 8:30 AM
Q3 25Nov 13, 25 | 8:30 AM
Q2 25Aug 12, 25 | 8:30 AM

Peer Comparison


TickerCompany
NNNNAnbio Biotechnology Class A Ordinary Shares
RGNXREGENXBIO Inc.
PACBPacific Biosciences of California, Inc.
VSTMVerastem, Inc.
MYGNMyriad Genetics, Inc.
ABSIAbsci Corporation
AVNSAvanos Medical, Inc.
FLGTFulgent Genetics, Inc.
INNVInnovAge Holding Corp.
OFIXOrthofix Medical Inc.